At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 667 enrolled
Drug / intervention
Erenumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention
In Brief
A Phase 2 clinical trial evaluating Erenumab and Placebo for Treatment for Prevention of Chronic Migraine. Completed, enrolled 667 participants across 74 sites in 10 countries.
Detailed Summary
To evaluate the effect of erenumab compared to placebo on the change from baseline in the number of monthly migraine days in adults with chronic migraine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Czechia, Denmark, Finland, Germany, Norway, Poland, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 2014
Enrollment StartMar 2014
Primary CompletionFeb 2016
Study CompletionApr 2016
TodayJul 2026
First PostedFeb 19, 2014
Enrollment StartMar 5, 2014
Primary CompletionFeb 24, 2016
Study CompletionApr 28, 2016
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 12.4 years ago
Interventions
Erenumabbiological
Administered once a month subcutaneously by authorized investigational site study staff.
Placebodrug
Administered once a month subcutaneously by authorized investigational site study staff.